The emergence of dual-action receptor agonists in the approach of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://iwanhxds873264.qowap.com/97796745/retatrutide-vs-tirzepatide-a-comparative-analysis